3 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
To demonstrate that the small dose of Picoprep (2 times 150 ml with 3-4 litres of clear fluids) is as efficacious for bowel cleansing as small dose Moviprep (PEG) (2 litre with 2 litres of clear fluids) and that Picoprep is as safe as Moviprep and…
MAIN OBJECTIVES:- To compare the efficacy of Dato-DXd in combination with pembrolizumab versus pembrolizumab alone, as measured by progression-free survival (PFS) by blinded independent central review (BICR).- To compare the efficacy of Dato-DXd in…